SCHEMBL3528005

SCHEMBL3528005

CCOc1cccc(C2(CC=O)CCN(C(=O)OC(C)(C)C)CC2)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.49
TACR1 P25103 1/20 0.46
OPRD1 P41143 1/20 0.43
OPRK1 P41145 1/20 0.43
TET3 O43151 1/20 0.43
FBXL19 Q6PCT2 1/20 0.43
CXXC5 Q7LFL8 1/20 0.43
TET1 Q8NFU7 1/20 0.43
KDM2B Q8NHM5 1/20 0.43
CXXC4 Q9H2H0 1/20 0.43
KDM2A Q9Y2K7 1/20 0.43
ATM Q13315 1/20 0.42
MMP13 P45452 1/20 0.42
CCR5 P51681 4/20 0.41
GPR119 Q8TDV5 2/20 0.41
TSHR P16473 2/20 0.40
ALOX15 P16050 1/20 0.40
EPHX2 P34913 4/20 0.39
ROCK2 O75116 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3529091 0.90 TACR1 (0.47) KMT2ATACR1OPRD1OPRK1ATM
SCHEMBL3529074 0.88 TACR1 (0.46) KMT2ATACR1OPRD1OPRK1ATM
SCHEMBL3531219 0.86 KMT2A (0.56) KMT2AOPRD1OPRK1TET3FBXL19
SCHEMBL3531065 0.85 TACR1 (0.48) TACR1OPRD1OPRK1ATMCCR5
SCHEMBL3528807 0.85 KMT2A (0.46) KMT2ATACR1OPRD1OPRK1TET3
SCHEMBL3525135 0.84 CCR5 (0.54) KMT2ATACR1OPRD1OPRK1ATM
SCHEMBL27621197 0.84 KMT2A (0.45) KMT2ATET3FBXL19CXXC5TET1
SCHEMBL3272198 0.84 TACR1 (0.58) TACR1OPRD1OPRK1ATMCCR5
SCHEMBL3525203 0.82 TACR1 (0.46) TACR1OPRD1OPRK1ATMCCR5
SCHEMBL3522779 0.82 GPR119 (0.52) TACR1GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-20060229336-A1 Ccr5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORPORATION 2006-10-12 US disclosed
EP-1569646-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2005-09-07 EP disclosed
WO-2004054974-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229336-A1 Ccr5 antagonists as therapeutic agents CCR5, CCR1, CXCR3 KMT2A 4565/4885TACR1 140/4885OPRD1 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.